123ArticleOnline Logo
Welcome to 123ArticleOnline.com!
ALL >> Business >> View Article

Harver Group Investing Heavily In Potential Cancer Cure

By Author: Harver Group
Total Articles: 26

Jul. 22, 2013 - CHUO-KU, Japan -- Harvard Bioscience Inc. (HBIO) has received little attention for their research from the medical establishment or from educational institutions. While posting consistent growth and a strong customer base, shareholders have not seen much profit to date due to operating losses from the company´s Regenerative Medical Device division also known as Harvard Apparatus Regenerative Technology.

“We believe that Harvard Bioscience Inc. is a solid investment now” said Peter Anderson Senior Vice President of Mergers and Acquisitions at Harver Group, “before Harvard Apparatus Regenerative Technology is given an initial public offering”.

Head of Investment Analysis, Mr. Nathan Marx said “Removing Harvard Apparatus from their balance sheets should lead to an increase in valuation of at least 50% in the short term and potentially 100% in the long term if shareholder friendly policies are enacted. We expect the IPO to happen within four months”.

Harvard Apparatus Regenerative Technology is pursing ground breaking research; they are preforming clinical trials of their cure for trachea cancer. The trials have produced very exciting results, with a high survival rate for a typically fatal form of cancer. They’ve created scaffolding, which in conjunction with cells from the patient construct a new trachea. This technology has further applications, for lung and heart, heart valve, liver, and kidney transplants as well as esophageal cancer.

Both the President and CFO of Harvard Bioscience Inc. will be leaving to run Harvard Apparatus Regenerative Technology. We believe that this indicates that a sale of Harvard Bioscience is in the works, due to the fact that the President and CFO along with other members of management own 14% of the company. Management will likely maximize value, and sell the company for at least $10 a share. We are recommending our clients to move on Harvard Bioscience Inc. as soon as possible and we will bring more news on Harvard Apparatus Research Technology IPO as we receive it.

Total Views: 84Word Count: 321See All articles From Author

Business Articles

1. Role Of Logistik Headhunter In Commercial Domains
Author: Ansel Adams

2. Lean Specialized Personnel Consulting And Role Of Consultant
Author: Ansel Adams

3. Time To Glide
Author: Christy Whitman

4. 5 Powerful Tips How To Hire The Right Process Server
Author: Unknown Member

5. Dog Services In Hyderabad -kennels9
Author: multail

6. Production House In Hyderabad - Multaistudios
Author: multail

7. Honda Of Valley Stream
Author: Honda of Valley Stream

8. Get More Choices With Confidential Invoice Factoring
Author: Ian Moore

9. Spray Coaters
Author: sateesh

10. Go Green Skateboard Longboarding
Author: For more details :- Mustang paddle shifter, Steeri

11. Al Ramziah Group Offers The Best Interior Cont Uae Services As Per The Clients Requirement
Author: charltonremus

12. Design Your Own T-shirt With Your Own Pattern
Author: Rhett Landers

13. Top 5 Simple And Effective B2b Seo Tips To Follow In 2018
Author: Epromotionz

14. Why Wholesale Salmon Oil
Author: For more details :- cod liver oil bulk, private la

15. Economical Omron Plc Models Price Compare To Omron Dealers In Chennai| Data Trace Automation.
Author: DTA

Login To Account
Login Email:
Password:
Forgot Password?
New User?
Sign Up Newsletter
Email Address: